Thailand’s New Cannabis Controls Impact Doctors, Dispensaries, and Growers

September 3, 2025

Thailand’s New Cannabis Controls Impact Doctors, Dispensaries, and Growers

Liberal cannabis access in Thailand is officially over. On June 26, 2025, the Ministry of Public Health brought the inflorescence of cannabis back under tight control through its new Notification on Controlled Herbs (Cannabis) 2025 (“Notification 2025”). The message is that cannabis may stay in the marketplace, but only if strictly supervised under a cannabis prescription from a medical professional. Two main pillars now define compliance: (1) prescription requirements and mandatory reporting, and (2) Good Agricultural and Collection Practices (GACP). This article aims to summarize each essential element for the relevant parties.

1. Getting a Prescription: Digital Diagnosis vs. Real-World Paperwork?

Dispensaries, even those with a license to sell cannabis, can no longer sell cannabis to walk-in customers who don’t have a valid prescription. Sales are lawful only when the buyer duly presents a cannabis prescription issued by one of seven recognized professional practitioners, including medical doctors, Thai traditional medicine doctors, applied Thai traditional medicine doctors, folk healers, Chinese medicine practitioners, pharmacists, or dentists.

Notification 2025 does not mention teleconsultations or online prescriptions. Nonetheless, policymakers at this stage opine that an online chat or casual consultation, with the prescription sent via a social media platform or e-mail, would not comply with this latest regulation. In order to be eligible to issue cannabis prescriptions, medical doctors should be working in a clinic or hospital and should issue paper-based prescriptions. The official prescription form, called a PT 33, must be used. The prescriber has the discretion to indicate the cannabis strain (or product type), dosage, and intended duration of use, which cannot exceed 30 days per prescription. This ensures that the product matches the patient’s medical needs and aligns with professional treatment guidelines. In practice, each prescription will be valid for one-time use only and cannot be refilled; a new prescription will be required for each subsequent use.

Dispensaries must retain every prescription for at least one year and must be able to present the prescriptions immediately upon request for inspection by the Department of Thai Traditional and Alternative Medicine (DTAM) or by a police officer. Because the controlled herbs regime treats cannabis flowers as a potentially divertible psychotropic drug, any lapse in identity verification (e.g., lack of a medical practitioner license number), signature integrity, or recordkeeping can lead to the suspension of the dispensary’s selling license. If a dispensary fails to follow the prescription’s instructions and requirements, the dispensary and its proprietor may be charged with an offense punishable by up to one year’s imprisonment or a THB 20,000 fine.

2. GACP: Shift from “Any Farm Will Do” to Standardized Agricultural Field

Another game-changing requirement is that cannabis flowers sold or exported must originate from a cultivation site certified under Good Agricultural and Collection Practices (GACP). In practical terms, the DTAM inspectors will audit and certify a site by reviewing the soil, water, pesticide use, worker hygiene, and postharvest handling. Certification under GACP is valid for one to three years, with annual surveillance. Growers must keep seed-to-sale records, including seed provenance, fertilizer logs, pest-management reports, harvest dates, and quality-control tests. Without GACP-validated evidence, downstream licenses (for dispensaries and for exporters) are exposed to a possible suspension.

Practical Takeaways

These significant changes to Thailand’s regulatory regime for cannabis have far-reaching implications for various businesses and professionals:

Medical professionals and clinics: These parties must understand and use the correct prescription form (PT 33) and keep a copy of the diagnostic evidence, as inspectors are likely to increasingly cross-check medical files against prescription volumes.
Dispensaries and budtenders: The role of the budtender is evolving from a retail assistant to a compliance-focused professional. Budtenders must be trained to verify the authenticity of prescriptions and buyers’ personal information, as well as confirming that products have been derived from a GACP field, in order to ensure that the dispensed products match every prescription’s details. They are also responsible for maintaining records and supporting regulatory inspections.
Growers: There must be a shift to treat GACP as a full-scale quality-management system, which would mean keeping continuous logs, submitting to internal audits, and participating in annual refresher training to keep updated on the latest regulatory requirements—none of which would be optional practices for a grower hoping to maintain GACP certification.

Future Direction

With Thailand’s tightening of cannabis regulations, many dispensaries in the country are expected to transition into the cannabis clinic business, particularly specializing in traditional Thai medicine. This shift will require additional licensing (i.e., for clinic establishment and clinic operations), the presence of qualified medical professionals, and compliance with the required medical standards. The integration of cannabis into traditional medicine clinics is seen as a sustainable model for the future, aligning with Thailand’s heritage and regulatory goals.

Related Professionals

Atthachai Homhuan

Director, Regulatory Affairs

Thailand

+66 2056 5610

Email

RELATED INSIGHTS

August 8, 2025

New Draft Regulatory Framework for Food Product Declaration and Registration in Vietnam

In response to persistent challenges in food safety management and recent high-profile incidents involving counterfeit supplemented foods, infant formula, and health supplements, the Ministry of Health of Vietnam is initiating comprehensive regulatory reforms. These reforms include proposed amendments to the Law on Food Safety and its implementing Decree No. 15/2018/ND-CP (Decree 15), introducing significant changes to the registration procedures for food products, especially supplemented food products and health supplements. While awaiting public consultation and approval of the amended Law on Food Safety, the Ministry of Health is developing an interim mechanism, which includes a draft decree to replace Decree 15 and a draft resolution to address urgent issues until the amended law becomes effective, expected in July 2026. To align with the new Law on Quality of Products and Goods, the draft resolution stipulates that the declaration and registration of food products will follow the following procedures: Declaration of applied standards for food products, which is currently known as the “self-declaration” procedure, applies to processed packaged foods, food additives, food processing aids, containers or utensils that come into direct contact with food, packaging materials in direct contact with food, and micronutrients. Granting of circulation numbers, which is the current “registration of product declaration” procedure, applies to specific categories of food including health supplements, medical nutrition foods, special dietary foods, nutritional products for children up to 36 months, and, especially, supplemented foods, which are currently subject to self-declaration but will be shifted to this registration procedure. In addition, the following new procedure is introduced in the draft decree: Registration of declaration of conformity, which applies to the same product category as in “declaration of applied standards” above, but is for products that are already subject to technical regulations covering both safety indicators and quality indicators. Changes to the Food Product

July 15, 2025

Vietnam Updates Guidelines on Drug Quality Standards, Testing, and Noncompliance

On July 1, 2025, Vietnam’s Ministry of Health issued Circular No. 30/2025/TT-BYT providing updated guidance on the application of drug quality standards, testing of drugs and pharmaceutical ingredients, and procedures for the recall and handling of noncompliant drugs (Circular 30). Circular 30 officially came into effect on the same day and replaces Circular No. 11/2018/TT-BYT and its amendments. Key highlights of Circular 30 are presented below. Drug and Pharmaceutical Ingredient Quality Standards Circular 30 maintains consistency with previous regulations regarding the selection of an applicable quality specification. Pharmaceutical businesses and drug preparation establishments may still choose to apply standards from the Vietnamese Pharmacopoeia, reference pharmacopoeias (including the United States Pharmacopoeia, the European Pharmacopoeia, the British Pharmacopoeia, the Japanese Pharmacopoeia, and the International Pharmacopoeia), or an in-house specification. Priority is given to the Vietnamese Pharmacopoeia and reference pharmacopoeias, encompassing quality indicators, quality levels, and testing methods. If alternative pharmacopoeias or in-house specifications are used, they must meet the requirements outlined in the corresponding monographs of the Vietnamese or reference pharmacopoeias. At the time of registration, the quality standards of drugs and pharmaceutical ingredients must comply with either the current version of the pharmacopoeia or a previous version of the pharmacopoeia that is no more than two years older than the current version. The requirement for updating quality specifications in line with the quality under the corresponding pharmacopoeia also applies to products that have already been granted marketing authorization. Testing Drugs and Pharmaceutical Ingredients in Quality Management Similar to the regulations under the previous circular, if pharmaceutical businesses disagree with the sample testing results, they may, within five working days of receiving the test report, request that the state quality inspection authority designate an alternative testing facility. The testing period for establishments listed as foreign drug manufacturers with quality violations remains

July 14, 2025

Pharmaceutical Data Exclusivity in Southeast Asia

Life sciences specialists from Tilleke & Gibbins have updated the firm’s guide to pharmaceutical data exclusivity regulations and practices in Southeast Asia. This guide contains quick-reference information on the availability of data exclusivity protections and limitations in Cambodia, Indonesia, Laos, Malaysia, Myanmar, Thailand, and Vietnam. Developing and launching a new drug on a commercial scale requires an enormous amount of time and investment in research and development (R&D), including pre-clinical testing and clinical trials. When considering the aggregate amount of drug development costs, it is important to recognize that this includes not only the investment in developing new drugs that get approved by a government food and drug regulator and are successfully brought to market, but also the R&D expenditures on a large number of potential pharmaceutical compounds and products that never actually make it to market. In particular, considerable investment is required in order to conduct and produce clinical trial data—to prove safety, efficacy and effectiveness of a new drug—that would warrant marketing approval by the regulatory authority. Such data is proprietary in nature and highly valuable for a research-based pharmaceutical company that develops an original drug. On the other hand, patent law typically confers generic drug manufacturers with the ability to engage in various preparatory activities with a view to obtaining marketing approval for a generic product before the patent for the original drug expires (commonly known as a “Bolar provision”). Since a generic drug maker may submit an application for marketing approval of a generic product before the relevant patent expires, the extent to which the drug originator’s data submitted to the regulatory authority is protected—or in other words, the extent to which the generic company may rely on the drug originator’s previously filed data, which underpins the safety and efficacy of the drug, to support

July 9, 2025

Vietnam Amends Key Aspects of Advertising Law

On June 16, 2025, the National Assembly of Vietnam adopted Law No. 75/2025/QH15 amending and supplementing a number of articles of the 2012 Advertising Law, with an effective date of January 1, 2026. The amended Advertising Law was enacted to further refine the legal framework for advertising activities in the modern era. Online Advertising Under the amended Advertising Law, “online advertising” is defined to encompass not only advertising on electronic newspapers and electronic information pages (as provided under the 2012 Advertising Law) but also advertising on other electronic venues, including social media, online applications, and digital platforms with internet connection. The amended Advertising Law also imposes new requirements for online advertising, including: Identification signs: Advertisements must have clear identifiable signs in numbers, letters, symbols, images, or sounds to distinguish them from non-advertising content. Control features: For advertisements not in fixed areas, there must be easily recognizable features and icons that allow recipients to turn off the advertisement, notify the service provider of violating advertising content, and refuse to view inappropriate advertising content. Linked content: Content in the links embedded in advertisements must comply with the law. Advertising service providers and publishers must have measures to check and monitor the linked content. Advertising on social media: Organizations and enterprises providing social media services must offer users features to distinguish advertising content from other content. Signage for sponsored content: When advertising, users of social media services must use signs to differentiate advertising or sponsored content from other content they provide. In response to the above requirements for online advertising, the amended Advertising Law sets out obligations of advertisers, advertising service providers, advertising publishers, and advertising conveyors in relation to online advertising. Among these, it is notably the responsibility of individuals and organizations engaging in online advertising to prevent and remove violating

You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

Industries

Practices

September 3, 2025